

# Haggard

Haggard is a wedge serifs typeface family of six styles. It stands out from the crowd with unique features like compact proportions of glyphs, sharp wedge serifs, small caps, and true italics. Haggard is a display font and can be used for editorial and print design.

Haggard Regular

*Haggard Italic*

**Haggard Bold**

***Haggard Bold Italic***

HAGGARD SC REGULAR

**HAGGARD SC BOLD**



We can't prevent, absolutely, another oil spill

# offshore oil

*we must minimize the risk to workers, habitat and wildlife*

THE GULF OF MEXICO IS A NATIONAL TREASURE

risk of our costly dependence on oil

# GULF OF MEXICO

*It is a unique natural resource that provides*

# AMERICANS

*with food, energy and jobs*

# *essential*

PROSPERITY, SECURITY AND WELFARE OF THE NATION

A B C D E F G H I J K L M N

O P Q R S T U V W X Y Z

a b c d e f g h i j k l m n o p

q r s t u v w x y z

1 2 3 4 5 6 7 8 9 0 , . : ; ! ? & \$ \*

*A B C D E F G H I J K L M N*

*O P Q R S T U V W X Y Z*

*a b c d e f g h i j k l m n o p*

*q r s t u v w x y z*

*1 2 3 4 5 6 7 8 9 0 , . : ; ! ? & \$ \**

A B C D E F G H I J K L M N

O P Q R S T U V W X Y Z

a b c d e f g h i j k l m n o p

q r s t u v w x y z

1 2 3 4 5 6 7 8 9 0 , . ; : ! ? & \$ \*

*A B C D E F G H I J K L M N*

*O P Q R S T U V W X Y Z*

*a b c d e f g h i j k l m n o p*

*q r s t u v w x y z*

*1 2 3 4 5 6 7 8 9 0 , . ; : ! ? & \$ \**

A B C D E F G H I J K L M N  
O P Q R S T U V W X Y Z

A B C D E F G H I J K L M N O P  
Q R S T U V W X Y Z

1 2 3 4 5 6 7 8 9 0 , . ; : ! ? & \$ \*

A B C D E F G H I J K L M N  
O P Q R S T U V W X Y Z

A B C D E F G H I J K L M N O P  
Q R S T U V W X Y Z

1 2 3 4 5 6 7 8 9 0 , . ; : ! ? & \$ \*

abcdefghijklmnopqrstuvwxyz

à á â ã ä å æ ç è é ê ë ì í î ï ð ñ ò ó ô õ ö ø œ þ š ß ù ú û ü  
ý ÿ ž fi fl

ABCDEFGHIJKLMNOPQRSTUVWXYZ

À Á Â Ã Ä Å Æ Ç È É Ê Ë Ì Í Î Ï Ñ Ò Ó Ô Õ Ö Ø Ù Ú Û Ü Ý Þ ß à á â ã

0123456789

# \$ ¢ £ ¥ € + ± × ÷ = < > ~ ^ ° ‰ ‰ 1 2 3 1/4 1/2 3/4 [ ] { } ( )

/|\|«»<>\_---@&!;?¿.....,:;\*®©™ªº

¶†‡§•,, ””“””\^~••/••○//√

A b j d e y 2 5

Regular/Italic 9/12 pt

It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.

*It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.*

Regular/Italic 11/15 pt

It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.

*It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.*



Nkqhcg26

Bold/Bold Italic 9/12 pt

It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.

*It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.*

Bold/Bold Italic 11/15 pt

It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.

*It turns out that many of the companies have been slack on following through with their post-marketing commitments. Out of the 49 accelerated approvals for cancer drugs – 29 of which were approved based on a single trial with no control arm to verify improvement – only 55% have completed post-marketing studies verifying benefit, Nature reports, while 10.2% failed in post-marketing studies. Others have yet to conduct the trials.*

R k Q 7 H c y 8

SC Regular/SC Bold 9/12 pt

IT TURNS OUT THAT MANY OF THE COMPANIES  
HAVE BEEN SLACK ON FOLLOWING THROUGH  
WITH THEIR POST-MARKETING COMMITMENTS.  
OUT OF THE 49 ACCELERATED APPROVALS FOR  
CANCER DRUGS – 29 OF WHICH WERE APPROVED  
BASED ON A SINGLE TRIAL WITH NO CONTROL  
ARM TO VERIFY IMPROVEMENT – ONLY 55%  
HAVE COMPLETED POST-MARKETING STUDIES  
VERIFYING BENEFIT, NATURE REPORTS, WHILE  
10.2% FAILED IN POST-MARKETING STUDIES.  
OTHERS HAVE YET TO CONDUCT THE TRIALS.

IT TURNS OUT THAT MANY OF THE COMPANIES  
HAVE BEEN SLACK ON FOLLOWING THROUGH  
WITH THEIR POST-MARKETING COMMITMENTS.  
OUT OF THE 49 ACCELERATED APPROVALS  
FOR CANCER DRUGS – 29 OF WHICH WERE  
APPROVED BASED ON A SINGLE TRIAL WITH  
NO CONTROL ARM TO VERIFY IMPROVEMENT –  
ONLY 55% HAVE COMPLETED POST-MARKETING  
STUDIES VERIFYING BENEFIT, NATURE  
REPORTS, WHILE 10.2% FAILED IN POST-  
MARKETING STUDIES. OTHERS HAVE YET TO  
CONDUCT THE TRIALS.

SC Regular/SC Bold 11/15 pt

IT TURNS OUT THAT MANY OF THE  
COMPANIES HAVE BEEN SLACK ON  
FOLLOWING THROUGH WITH THEIR  
POST-MARKETING COMMITMENTS.  
OUT OF THE 49 ACCELERATED  
APPROVALS FOR CANCER DRUGS – 29  
OF WHICH WERE APPROVED BASED ON  
A SINGLE TRIAL WITH NO CONTROL ARM  
TO VERIFY IMPROVEMENT – ONLY 55%  
HAVE COMPLETED POST-MARKETING  
STUDIES VERIFYING BENEFIT, NATURE  
REPORTS, WHILE 10.2% FAILED IN  
POST-MARKETING STUDIES. OTHERS  
HAVE YET TO CONDUCT THE TRIALS.

IT TURNS OUT THAT MANY OF THE  
COMPANIES HAVE BEEN SLACK ON  
FOLLOWING THROUGH WITH THEIR  
POST-MARKETING COMMITMENTS.  
OUT OF THE 49 ACCELERATED  
APPROVALS FOR CANCER DRUGS – 29  
OF WHICH WERE APPROVED BASED ON  
A SINGLE TRIAL WITH NO CONTROL  
ARM TO VERIFY IMPROVEMENT –  
ONLY 55% HAVE COMPLETED POST-  
MARKETING STUDIES VERIFYING  
BENEFIT, NATURE REPORTS, WHILE  
10.2% FAILED IN POST-MARKETING  
STUDIES. OTHERS HAVE YET TO  
CONDUCT THE TRIALS.

“Darling,  
have you  
eaten?  
You look  
haggard.”

*From movie “The Birdcage”*

Tipografia  
Ramis  
Guseynov

Typeface Haggard in six styles.

Available at [MyFonts.com](http://MyFonts.com)

TipografiaRamis

© 2011 by Ramiz Guseynov.

All rights reserved.